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Background: Airway accumulation of eosinophils and bronchial hyperresponsiveness (BHR) are promi-
nent features of bronchial asthma, though the contribution of eosinophils to the development of BHR is
controversial. Similar to Th2 cell-mediated pathology, Th9 cells, characterized by IL-9-producing activity,
have been demonstrated to induce airway eosinophilia and BHR. In this study, we investigated the role of
eosinophils in Th9-mediated BHR by employing Th9 cell-transferred murine airway inﬂammation model.
Methods: Ovalbumin (OVA)-speciﬁc Th2 and Th9 cells were differentiated from CD4þ T cells of DO11.10/
RAG-2/ mice in vitro and cytokine-producing activity of those cells was examined. BALB/c mice were
adoptively transferred with Th2 or Th9 cells and challenged with OVA. Then, the number of inﬂam-
matory cells in bronchoalveolar lavage ﬂuid and bronchial responsiveness to inhaled methacholine were
determined.
Results: Both in Th2 and Th9 cell-transferred mice, substantial accumulation of eosinophils in the lungs
and BHR were induced by challenge with speciﬁc antigen. Nevertheless, an essential and dispensable role
of eosinophils in Th2- and Th9-mediated BHR, respectively, was demonstrated by employing eosinophil-
deﬁcient mice. The neutralization of IL-9 as well as deﬁciency of IL-10 in the donor cells did not affect
Th9-mediated BHR.
Conclusions: In contrast to Th2-mediated and eosinophil-dependent BHR, Th9 could induce BHR inde-
pendently from eosinophils and its characteristic cytokines, IL-9 and IL-10.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bronchial asthma is a chronic inﬂammatory disease character-
ized by reversible airway obstruction and bronchial hyper-
responsiveness (BHR) associated with eosinophilic inﬂammation.
Th2 cells have been recognized to regulate pathological features of
this disease by secreting cytokines such as IL-4, IL-5, and IL-13.1e4
These cytokines induce a variety of responses including IgE pro-
duction as well as airway eosinophilia, mucus production, and
remodeling. Human asthma-like Th2-type airway inﬂammationProject, Tokyo Metropolitan
etagaya-ku, Tokyo 156-8506,
i).
ety of Allergology.
rgology. Production and hosting by Elsecould be reproduced in mouse models. Thus, antigen-induced
eosinophil accumulation in the lungs accompanied by signiﬁcant
BHR was observed in mice transferred with in vitro-differentiated
antigen-speciﬁc Th2 cells.5,6
Activated eosinophils have been implicated in asthma patho-
genesis. It has been recognized that BHR is mediated by accumu-
lated eosinophils in the lungs of asthmatic patients.7 However,
recent conﬂicting ﬁndings in several clinical studies using
neutralizing antibodies (Abs) against eosinophil-active cytokines
have unstabilized the contribution of eosinophils to BHR.8e11 Such
controversy has been seen also in animal studies.12
We have also investigated the contribution of eosinophils to
BHR, especially in a Th2-mediated murine airway inﬂammation
model. Thus, using eosinophil-deﬁcient mice inwhich double GATA
site in the GATA-1 gene was deleted (DdblGATA) as the re-
cipients,13,14 attenuated antigen-induced BHR was observed. Invier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1
Cytokine production by Th2 and Th9 cells.
Concentration (ng/ml) p value
Th2 Th9
IL-4 611.4 ± 20.1 118.2 ± 1.5 0.002
IL-5 45.1 ± 3.1 16.4 ± 0.1 0.012
IL-9 1.9 ± 1.0 9.2 ± 1.0 0.006
IL-10 156.5 ± 36.9 85.5 ± 1.7 0.195
In vitro-differentiated Th2 and Th9 cells were cultured with X-ray irradiated sple-
nocytes in the presence of OVA323-339 peptide. Seventy-two hours later, the
concentrations of cytokines in the culture supernatants were measured by ELISA.
Data are expressed as mean ± SEM of triplicate cultures. The results shown are
representatives of three separate experiments.
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expressed on eosinophils, signiﬁcantly suppressed Th2-mediated
BHR along with the reduction of airway eosinophil accumula-
tion.5 These ﬁndings support the critical role of accumulated eo-
sinophils induced by Th2 cells in the development of BHR.
In addition to well-known T cell subsets such as Th1, Th2, and
Th17, a new subset characterized by IL-9-producing activity has
recently been identiﬁed and termed as Th9 cells.15,16 Th9 cells are
developed from naive CD4þ T cells by priming with IL-4 and
transforming growth factor-b (TGF-b). Similar to Th2 cell-mediated
models, mice transferred with Th9 cells develop asthma-like
airway inﬂammation characterized by eosinophil inﬁltration and
BHR in response to airway antigen challenge.17 In addition, IL-9
induces the expression of mucus genes in airway epithelial
cells.18e21 Therefore, Th9 cell is recognized as one of the key players
and a target for the treatment of bronchial asthma.22,23
However, also in the case of Th9-mediated pathogenesis, it has
not been determined whether eosinophils play a role in the
development of BHR. Here, we investigated the mechanisms of Th9
cell-mediated BHR including the contribution of eosinophils by
employing eosinophil-deﬁcient mice, anti-IL-9 neutralizing Ab, and
IL-10-deﬁcient Th9 cells in the Th9 cell-transferred murine model
of airway inﬂammation.
Methods
Experimental animals
All animal experiments were performed in accordance with
guidelines approved by the animal use committee at Tokyo
Metropolitan Institute of Medical Science. DO11.10/RAG-2/, IL-
10//DO11.10/RAG-2/, and DdblGATA mice of BALB/c back-
ground were maintained as described previously.6,14,24
In vitro T cell differentiation
After depletion of erythrocytes, CD4þ T cells were isolated from
splenocytes of DO11.10/RAG-2/ and IL-10//DO11.10/RAG-2/
mice by using anti-mouse CD4 Ab-conjugated magnetic beads and
magnetic cell sorting system (Miltenyi, Bergisch Gladbach, Ger-
many). Then, cells were cultured in the presence of X-ray-irradiated
syngeneic spleen cells as antigen-presenting cells and 0.3 mM
OVA323-339 peptide in DMEM-F12/HAM medium (Sigma-Aldrich,
MO, USA) supplemented with 10% fetal bovine serum, penicillin,
streptomycin, L-glutamine, HEPES, pyruvate, and 2-
mercaptoethanol. Th2 differentiation was introduced by adding
10 U/ml recombinant human IL-2 (Shionogi, Osaka, Japan) and
mouse IL-4 (PeproTech, NJ, USA) and 10 mg/ml anti-IFN-g mono-
clonal Ab (mAb) (R4-6A2, eBioscience, CA, USA) as described pre-
viously.6,24 Th9 cells were differentiated by adding 10 U/ml IL-2 and
IL-4, 5 ng/ml recombinant mouse TGF-b (R&D Systems, MN, USA),
and 10 mg/ml anti-IFN-g mAb. Cells were cultured for 7 days and
then used for the adoptive transfer. To determine the integrity of
polarization, cells (1  105) were incubated with irradiated sple-
nocytes (2  105) with or without 0.3 mMOVA peptide for 72 h. The
culture supernatants were collected to determine cytokine pro-
duction by ELISA using mouse ELISA kits (eBioscience and Bio-
Legend, CA, USA) according to the manufacturer's instructions.
Cell transfer and antigen challenge
Cells (1  107) suspended in phosphate-buffered saline were
intravenously (i.v.) injected in the recipient mice. One day after the
cell transfer, the mice were challenged with intratracheal injection
of OVA solution (25 mL, 15 mg/ml in saline) using a MicroSprayeraerosolizer (Penn Century Inc., PA, USA) under isoﬂurane anes-
thesia as described previously.25 To neutralize IL-9, mice were
administered with either 6 mg/kg (i.v.) anti-IL-9 (BioLegend,
#504802) or isotype control Ab 2 h before the OVA challenge.Bronchoalveolar lavage ﬂuid analysis
Seventy-two hours after the antigen challenge, bronchoalveolar
lavage was performed by introducing 3  0.5 ml phosphate-
buffered saline into the lung via a tracheal cannula. The number
of leukocytes in bronchoalveolar lavage ﬂuid (BALF) was counted
using a hemocytometer. Then, differential cell counts based on
morphologic criteria were performed for at least 200 cells on a
cytocentrifuged preparation after staining with Diff-Quick (Sysmex
Corporation, Kobe, Japan). The number of transferred T cells in BALF
was determined by ﬂow cytometry upon staining with anti-CD4-
APC-eFluor780 (eBioscience) and anti-KJ1-26-PE (BioLegend).Measurement of bronchial hyperresponsiveness
Seventy-two hours after the antigen challenge, mice were
anesthetized by intraperitoneal injection of 100 mg/kg sodium
pentobarbital (Kyoritsu Seiyaku, Tokyo, Japan) and then a 19-gauge
cannula was inserted into the trachea. Mechanical ventilation was
performed under diaphragmatic perforation using a small animal
ventilator (FlexiVent; SCIREQ, Quebec, Canada) at a respiratory rate
of 150 breaths/min, a tidal volume of 10 ml/kg body weight, and a
positive end expiratory pressure of 3 cmH2O. BHR was assessed by
measuring progressive change in respiratory system resistance
(Rrs) following inhalation of increasing doses of aerosolized
methacholine (MCh; Nacalai tesque, Kyoto, Japan) through an in-
line nebulizer.Lung histology
Lung tissues were ﬁxed in 4% paraformaldehyde, and embedded
in parafﬁn. Tissue sections (4 mm) were stained with hematoxylin
and eosin (H&E) or periodic acid-Schiff (PAS) by the standard
procedure.Statistical analysis
The results are presented as arithmetic mean ± standard error of
mean (SEM). Statistical analysis was performed using Student's t-
test or one-way analysis of variance and Dunnett's multiple com-
parison test. p values less than 0.05 were considered to indicate
statistical signiﬁcance.
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Fig. 2. Effect of anti-IL-9 Ab on Th9-mediated BHR. Th9 cell-transferred DdblGATA mice were challenged with OVA or saline. Seventy-two hours after the challenge, inﬂammatory
cells recovered in BALF were differentially counted (A) and bronchial responsiveness to inhaled MCh was assessed (B). Data are expressed as mean ± SEM of 3e7 animals. N.D., not
detectable.
Fig. 3. Antigen-induced airway inﬂammation in IL-10-deﬁcient Th9 cell-transferred mice. IL-10/ Th9 cell-transferred WT and DdblGATA mice were challenged with OVA or saline.
Seventy-two hours after the challenge, inﬂammatory cells recovered in BALF were differentially counted (A) and bronchial responsiveness to inhaled MCh was assessed. The data of
IL-10þ/þ Th9 cell-transferred and antigen-challenged WT mice shown in Fig. 1D were also inset for the comparison (B). Data are expressed as mean ± SEM of 3e7 animals. *p < 0.05,
compared with saline-challenged WT mice. yp < 0.05, zp < 0.01, compared with saline-challenged DdblGATA mice. N.D., not detectable.
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Characterization of differentiated T cells in vitro
To evaluate the phenotypes of in vitro-differentiated Th2 and
Th9 cells, their cytokine-secreting proﬁles were examined. CD4þ TFig. 1. Antigen-induced airway inﬂammation in Th2 and Th9 cell-transferred mice. Th2 (A,
saline. Seventy-two hours after the challenge, inﬂammatory cells recovered in BALF were diff
D). H&E-stained (upper panels) or PAS-stained (lower panels) lung sections were observed
cell-transferred WT mice was examined by ﬂow cytometry (F). Data are expressed as mea
challenged WT mice. yp < 0.05, zp < 0.01, compared with saline-challenged DdblGATA mic
detectable.cells differentiated into Th2 cells produced IL-4, IL-5, and IL-10, and
a small amount of IL-9 upon stimulation with OVA (Table 1). In
contrast, the cells grown under the Th9 conditions produced sub-
stantial amounts of IL-9 and IL-10 though their IL-4- and IL-5-
producing activity were signiﬁcantly lower than Th2 cells. Detect-
able amounts of those cytokines were not produced by Th2 and Th9B) or Th9 (C, D) cell-transferred WT and DdblGATA mice were challenged with OVA or
erentially counted (A, C) and bronchial responsiveness to inhaled MCh was assessed (B,
under microscopy (E). The number of infused T cells recovered in BALF of Th2 and Th9
n ± SEM of 3e10 animals. *p < 0.05, **p < 0.01, ***p < 0.001, compared with saline-
e. ##p < 0.01, compared with antigen-challenged Th2 cell-transferred mice. N.D., not
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the typical Th2 and Th9 cells were developed under the appropriate
culture conditions in vitro.
Antigen-induced airway inﬂammation in Th2 and Th9 cell-
transferred wild-type and eosinophil-deﬁcient mice
The inﬁltration of inﬂammatory cells into the lungs was deter-
mined in Th2 or Th9 cell-transferred mice. Large numbers of eo-
sinophils, lymphocytes, and neutrophils were recovered in BALF of
antigen-challenged both mice (Fig. 1A, C). The bronchial respon-
siveness to inhaled MCh was similarly augmented in Th2- and Th9-
transferred mice by OVA challenge (Fig. 1B, D). Antigen-speciﬁc
immunoglobulins were not produced in this short-term experi-
mental procedure (data not shown). These results are consistent
with previous reports showing the critical role of Th2 and Th9 cells
in the development of eosinophilic inﬂammation accompanied by
BHR14,26 and suggest that Th2 and Th9 cells enable to induce airway
eosinophil accumulation and BHR by themselves without assis-
tance of IgE and other antigen-speciﬁc immunoglobulins.
Next, to examine the contribution of eosinophils to BHR induced
by Th2 and Th9 cells, these cells were transferred to DdblGATA
mice. Although eosinophils were not detectable in BALF of Th2- and
Th9-transferred DdblGATA mice even after OVA challenge, there
was no major difference in the inﬁltration of other inﬂammatory
cells between wild-type (WT) and DdblGATA mice (Fig. 1A, C).
Nevertheless, the role of eosinophils in BHR was different in Th2-
and Th9-mediated airway inﬂammation. In agreement with our pre-
vious study,14 antigen-induced increase in bronchial responsiveness
was not observed in Th2 cell-transferred DdblGATA mice (Fig. 1B).
Nevertheless, the equivalent antigen-induced BHR was developed in
WT and DdblGATA mice by using Th9 as donor cells (Fig. 1D).
H&E staining of the lungs illustrated that the same level peri-
vascular and peribronchial inﬂammation was developed in Th2-
and Th9-transferred WT and DdblGATA mice after OVA challenge
even without the inﬁltration of eosinophils (Fig. 1E). Antigen-
induced hyperplasia of PAS-positive goblet cells was also similarly
observed in the airway epithelium of those mice. These data sug-
gest that Th9 cell-mediated BHR is not dependent on eosinophils
accumulated in the lungs, in contrast to eosinophil-dependent BHR
induced by Th2 cells.
To investigate the direct contribution of antigen-speciﬁc T cells
to the development of BHR, we next examined OVA-induced
migration of transferred T cells in the lungs. The non-speciﬁc dis-
tribution of Th9 cells was observed in saline-challengedWTmice to
some degree. The signiﬁcant inﬁltration of infused T cells was
induced in Th2-transferred mice by OVA challenge, though it was
more efﬁciently induced in Th9-transferred mice (Fig. 1F).
Role of IL-9 and IL-10 in Th9 cell-mediated BHR
IL-9 and IL-10 produced by activated Th9 cells have been
implicated in asthma pathogenesis,22,23 therefore the contribution
of these cytokines to the development of Th9-mediated BHR was
evaluated. Th9 cell-transferred DdblGATA mice were challenged
with OVA after the treatment with anti-IL-9 Ab. There was nomajor
difference in antigen-induced BHR between anti-IL-9- and control
IgG-treated mice (Fig. 2). Two other anti-IL-9 Abs also failed to
affect Th9-mediated BHR (data not shown).
Th9 cells established from IL-10//DO11.10/RAG-2/ mice
were transferred to WT and DdblGATA mice, and then these mice
were challenged with OVA. Essentially same as the case that IL-10þ/
þ Th9 cells were used as donor cells (Fig. 1A), the equivalent inﬁl-
tration of inﬂammatory cells except for eosinophils was observed in
the lungs of DdblGATA and WT mice (Fig. 3A). Antigen-inducedBHR was rather augmented by IL-10 deﬁciency in donor Th9 cells
but was not affected by using DdblGATA mice as the recipient
(Fig. 3B). These data suggest that the development of BHR was not
caused by IL-9 and IL-10 produced from Th9 cells.
Discussion
Although inﬂammatory features including eosinophil accumu-
lation and BHR shown in Th2- and Th9-mediated airway inﬂam-
mation quite resemble each other, whether the same mechanisms
underlie the both responses has not been clariﬁed. In this study, we
elucidated that Th9 cell-mediated BHR, in contrast to Th2-mediated
response, was not dependent on eosinophils inﬁltrated in the lungs.
Several attempts to treat bronchial asthma through the inter-
vention of eosinophil-active cytokines have been performed.
However, clinical studies demonstrating the decreased sputum
eosinophils but unchanged BHR by the treatment with anti-IL-5 Ab
made the contribution of eosinophils to BHR doubtful.9e11
Considering our present ﬁndings showing the independency of
Th9-mediated BHR from eosinophils, the efﬁcacy of such
eosinophil-targeted therapy might not be expected for some
asthma endotypes in which the participation of Th9 cells is rela-
tively high. Since it has recently been elucidated that anti-IL-5
therapy is effective for steroid-dependent asthmatic patients,27,28
down-regulation of Th9 activity might be induced by the steroid
treatment in those patients.
The mechanisms by which Th9 cells induced BHR without
assistance of eosinophils were not completely evaluated in this
study. However, several cytokines such as IL-13, IL-17A, and TNF-a
directly regulate BHR by increasing calcium sensitivity of airway
smooth muscle cells through signaling pathways involving NF-kB,
RhoA, and ROCK2.29e32 Here we showed that Th9 cells more efﬁ-
ciently migrated in the lungs than Th2 cells upon antigen provo-
cation. Therefore, Th9 may directly affect the contractile activity of
airway smooth muscle by secreting its speciﬁc cytokines.
In this regard, Th9 cells predominantly secrete IL-9 and IL-10. IL-
10 modulates many cell activities that are implicated in allergic
diseases. Increased IL-10 in the lungs could diminished allergic
airway inﬂammation.33 Repeated airway antigen exposure leads
tolerance via the induction of IL-10-secreting regulatory T cells.34
Paradoxically, Justice et al. and M€akel€a et al. showed that antigen-
induced BHR was attenuated by IL-10 gene disruption.35,36 Our
present ﬁndings that Th9-mediated BHR was not suppressed but
rather augmented by deﬁciency of IL-10 support the negative role
of IL-10 in the development of airway inﬂammation.
The essential contribution of IL-9 to Th9-mediated BHRwas also
dismissed by its neutralizing experiment. However, our ﬁndings are
contradictory to the report of Staudt et al. demonstrating the down-
regulation of BHR by anti-IL-9 Ab.26 Although the correct reason for
the discrepancy was unclear, Staudt et al. used RAG-2/mice as the
Th9 cell recipients and challenged antigen for 6 consecutive days.
The chronic antigen exposuremight elevate the dependency of BHR
on IL-9. Further investigation with bewaring the differences in
experimental conditions employed by Staudt et al. and us may be
required to elucidate the exact role of IL-9 in the development of
BHR.
In addition to IL-9 and IL-10, the expression of several genes
encoding inﬂammatory mediators was recently identiﬁed in Th9
cells by microarray analysis.37 Therefore, unknown mediators
might play a role in BHR induced by Th9 cells.
In conclusion, unlikely to Th2-mediated response, Th9-
mediated BHR was independent of eosinophils accumulated into
the lungs. The elucidation of the mechanisms underlying Th9-
mediated BHR is favorable to the development of a novel thera-
peutic strategy for bronchial asthma.
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